CS585 IS A NOVEL ORALLY AVAILABLE PROSTACYCLIN RECEPTOR AGONIST WITH LONG-TERM IN VIVO INHIBITION OF PLATELETS AND THROMBOSIS FORMATION IN MOUSE WITHOUT INCREASED RISK OF BLEEDING

Michael Holinstat(Thomas Jefferson University), Björn Dahlöf(Sahlgrenska University Hospital), Adriana Yamaguchi(University of Michigan), Sylviane Lambert(University of Michigan), Pooja Yalavarthi(University of Michigan), Livia Stanger(University of Michigan)

Journal of the American College of Cardiology

March 1, 2023

10.1016/s0735-1097(23)02480-4

Cited by 0

Related Papers

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

|The Lancet|1998|5.8k

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

|The Lancet|2005|2.9k

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|1.6k

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

|The Lancet|2010|518

An age-progressive platelet differentiation path from hematopoietic stem cells causes exacerbated thrombosis

|Cell|2024|102